UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the fiscal year ended December 31, 2018 or Form 10-K ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2018 Earnings Conference Call February 28, 2019 5:00 PM ET Company Participants Jennifer Ruddock ??? Head-Investor Relations Howard Robin ??? President and Chief Executive Officer Mary Tagliaferri ??? Chief Medical Officer Gil Labrucherie ??? Chief Financial Officer Jonathan Zalevsky ??? Chief Scientific Officer Conference Call Participants Jessica Fye ??? JPMorgan Chris Shibutani ??? Cowen Paul Choi ??? Goldman Sachs George Farmer ??? BMO Capital Markets Alexander Dunca ...

| --- | --- | |-------|-----------------------------------| | | | | | 37th Annual | | | J.P. Morgan Healthcare Conference | | | Howard Robin | | | President & CEO | | | January 8, 2019 | 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and thes ...